Breakthrough may lead to anti-stroke vaccine

EU-funded scientists have discovered that the presence of low levels of a type of antibody in the immune system increases the chance of having a stroke, one of the leading causes of death worldwide. The finding, published in the journal Stroke, signals hope the development of a vaccine that can activate the body's natural defences against the condition.

The breakthrough is part of CVDIMMUNE (Immunomodulation and autoimmunity in cardiovascular disease and atherosclerosis), a project funded EUR 2.7 million under the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6).

In the past, researchers from Karolinska Institutet in Sweden (the project's coordinating institution) were able to prove that the presence of high levels of an antibody, known as anti-PC, in the human body's immune system reduced the risk of arteriosclerosis. Arteriosclerosis occurs when plaque builds up on blood vessel walls. These plaques can rupture and develop into a blood clot. Atherosclerosis, which is a form of arteriosclerosis, is the most common cause of cardiovascular disease.

In the current study, the CVDIMMUNE team turned their attention to strokes, and discovered a similar outcome; people with low anti-PC levels were at an increased the risk of stroke. Lower levels of these natural antibodies, which could be the result of an unhealthy immune system, can therefore contribute to the onset of both arteriosclerosis and stroke.

The research, which involved a comparison study of 227 first-time stroke victims with 445 controls over a 13-year period (between 1985 and 1999), also demonstrated that the link between low anti-PC levels and stroke risk was particularly strong for women.

The results have opened the door to several possibilities. Measurements of anti-PC could now be used by doctors to identify those who are at greater risk of stroke, such as immunodeficient individuals. Likewise, the potential now exists for novel modes of treatment, such as immunotherapies.

Head of the study, Professor Johan Frostegård, said: "We're now examining the possibility of developing new immunological treatments for arteriosclerosis and stroke, either in the form of a vaccine to stimulate the immune defence or immunisation through the injection of antibodies."

The World Health Organization (WHO) estimates that 15 million people across the world suffer a stroke ever year. One third of these people die, and an additional third are left with some form of permanent disability. High blood pressure is believed to be the main culprit, contributing to almost 13 million of these strokes.

In Europe, the WHO estimates that strokes are responsible, on average, for 650,000 deaths every year. Quit-smoking campaigns and efforts focused on lowering blood pressure have helped reduce the incidence of stroke in developed countries. Due to the advent of an ageing population, however, the threat of stroke remains high in these countries.

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...